<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8"><meta name="viewport" content="width=device-width, initial-scale=1.0"><meta name="apple-mobile-web-app-capable" content="yes">
    <title>üéß Heme/Onc Study Guide ‚Äî Audio Edition</title>
    <style>
        :root { --primary: #dc2626; --primary-light: #f87171; --accent: #e07b53; --bg: #1a1a2e; --card-bg: #16213e; --text: #e8e8e8; --text-muted: #a0a0a0; --border: #2d3a4f; }
        * { box-sizing: border-box; margin: 0; padding: 0; }
        body { font-family: -apple-system, sans-serif; background: var(--bg); color: var(--text); line-height: 1.8; padding: 20px; padding-bottom: 200px; font-size: 18px; }
        .header { text-align: center; padding: 30px 20px; background: linear-gradient(135deg, var(--primary), var(--primary-light)); border-radius: 16px; margin-bottom: 20px; }
        .header h1 { font-size: 1.5rem; margin-bottom: 8px; }
        .audio-controls { position: fixed; bottom: 0; left: 0; right: 0; background: rgba(22,33,62,0.98); padding: 15px 20px; padding-bottom: max(15px, env(safe-area-inset-bottom)); border-top: 1px solid var(--border); z-index: 1000; }
        .controls-row { display: flex; align-items: center; justify-content: center; gap: 15px; margin-bottom: 10px; }
        .control-btn { background: var(--primary); border: none; color: white; width: 50px; height: 50px; border-radius: 50%; font-size: 1.3rem; cursor: pointer; display: flex; align-items: center; justify-content: center; }
        .control-btn.play-btn { width: 65px; height: 65px; font-size: 1.6rem; background: var(--accent); }
        .progress-section { display: flex; align-items: center; gap: 10px; font-size: 0.8rem; color: var(--text-muted); }
        .progress-bar { flex: 1; height: 6px; background: var(--border); border-radius: 3px; cursor: pointer; }
        .progress-fill { height: 100%; background: var(--accent); width: 0%; }
        .current-topic { text-align: center; font-size: 0.85rem; color: var(--accent); margin-top: 8px; }
        .settings-row { display: flex; justify-content: center; gap: 20px; margin-top: 10px; }
        .speed-control select, .pause-control select { background: var(--card-bg); color: var(--text); border: 1px solid var(--border); padding: 6px 10px; border-radius: 8px; }
        .section { background: var(--card-bg); border-radius: 12px; margin-bottom: 20px; }
        .section-header { background: var(--primary); padding: 15px 20px; font-size: 1.1rem; font-weight: 600; display: flex; justify-content: space-between; }
        .section-content { padding: 20px; }
        .topic { margin-bottom: 25px; padding-bottom: 20px; border-bottom: 1px solid var(--border); }
        .topic:last-child { border-bottom: none; }
        .topic-title { font-size: 1.1rem; font-weight: 600; color: var(--accent); margin-bottom: 15px; }
        .content-block { margin-bottom: 15px; padding: 15px; background: rgba(255,255,255,0.03); border-radius: 8px; border-left: 3px solid var(--primary); }
        .content-block.high-yield { border-left-color: #ef4444; background: rgba(239, 68, 68, 0.1); }
        .block-label { font-size: 0.75rem; text-transform: uppercase; color: var(--text-muted); margin-bottom: 8px; }
        .current { background: rgba(220, 38, 38, 0.3); border-radius: 3px; }
        .voice-selector { margin: 15px 0; padding: 15px; background: var(--card-bg); border-radius: 12px; }
        .voice-selector select { width: 100%; padding: 10px; background: var(--bg); color: var(--text); border: 1px solid var(--border); border-radius: 8px; }
        .toc { background: var(--card-bg); border-radius: 12px; padding: 20px; margin-bottom: 20px; }
        .toc-item { padding: 10px 15px; margin: 5px 0; background: rgba(255,255,255,0.03); border-radius: 8px; cursor: pointer; display: flex; justify-content: space-between; }
        .toc-item.active { background: var(--primary); }
    </style>
</head>
<body>
<div class="header"><h1>ü©∏ Heme/Onc Study Guide</h1><p>Audio Edition ‚Ä¢ ABIM Board Review ‚Ä¢ 8% of Exam</p><p style="font-size:0.8rem; opacity:0.7; margin-top:8px;">v1.0 BUILD #8</p></div>
<div class="voice-selector"><label>üéôÔ∏è Voice:</label><select id="voiceSelect"></select></div>
<div class="toc"><h2>üìã Chapters</h2>
    <div class="toc-item" data-section="0"><span>1. Anemia</span><span>~7 min</span></div>
    <div class="toc-item" data-section="1"><span>2. Coagulation Disorders</span><span>~6 min</span></div>
    <div class="toc-item" data-section="2"><span>3. Thrombocytopenia</span><span>~6 min</span></div>
    <div class="toc-item" data-section="3"><span>4. VTE & Anticoagulation</span><span>~6 min</span></div>
    <div class="toc-item" data-section="4"><span>5. Hematologic Malignancies</span><span>~7 min</span></div>
    <div class="toc-item" data-section="5"><span>6. Transfusion Medicine</span><span>~5 min</span></div>
</div>
<div id="audioContent">
<div class="section" data-section="0">
    <div class="section-header"><span>1. Anemia</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Approach to Anemia</div>
            <div class="content-block"><div class="block-label">Classification by MCV</div>
                <p class="speakable">Microcytic anemia with MCV less than 80 is caused by iron deficiency, thalassemia, anemia of chronic disease, sideroblastic anemia, and lead poisoning.</p>
                <p class="speakable">Normocytic anemia is caused by acute blood loss, hemolysis, anemia of chronic disease, bone marrow failure, and chronic kidney disease.</p>
                <p class="speakable">Macrocytic anemia with MCV greater than 100 is caused by B12 deficiency, folate deficiency, hypothyroidism, liver disease, myelodysplastic syndrome, and medications.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Iron Deficiency Anemia</div>
            <div class="content-block high-yield"><div class="block-label">Diagnosis</div>
                <p class="speakable">Classic iron studies show low ferritin, low iron, high TIBC, and low transferrin saturation.</p>
                <p class="speakable">Ferritin is the most sensitive test but is an acute phase reactant and may be falsely normal in inflammation.</p>
                <p class="speakable">In inflammatory states, ferritin less than 100 suggests iron deficiency. Transferrin saturation less than 20 percent also supports the diagnosis.</p>
                <p class="speakable">Always investigate for GI blood loss in men and postmenopausal women with iron deficiency.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Hemolytic Anemia</div>
            <div class="content-block high-yield"><div class="block-label">Workup</div>
                <p class="speakable">Hemolysis shows elevated LDH, elevated indirect bilirubin, low haptoglobin, elevated reticulocyte count, and spherocytes on smear.</p>
                <p class="speakable">Direct Coombs test, or DAT, distinguishes immune from non-immune causes. Positive DAT indicates autoimmune hemolytic anemia.</p>
                <p class="speakable">Warm AIHA is IgG-mediated and associated with lymphoproliferative disorders. Treat with steroids, then rituximab.</p>
                <p class="speakable">Cold agglutinin disease is IgM-mediated and associated with Mycoplasma and lymphoma. Avoid cold, treat underlying cause, rituximab for severe cases.</p>
            </div>
        </div>
    </div>
</div>
<div class="section" data-section="1">
    <div class="section-header"><span>2. Coagulation Disorders</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Approach to Bleeding</div>
            <div class="content-block"><div class="block-label">PT vs PTT</div>
                <p class="speakable">Elevated PT with normal PTT suggests factor VII deficiency, warfarin effect, early liver disease, or early vitamin K deficiency.</p>
                <p class="speakable">Elevated PTT with normal PT suggests hemophilia A or B, von Willebrand disease, or heparin effect.</p>
                <p class="speakable">Both PT and PTT elevated suggests common pathway defects, DIC, severe liver disease, or supratherapeutic anticoagulation.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Von Willebrand Disease</div>
            <div class="content-block high-yield"><div class="block-label">Diagnosis and Treatment</div>
                <p class="speakable">VWD is the most common inherited bleeding disorder. Type 1 is most common with partial quantitative deficiency.</p>
                <p class="speakable">Presents with mucocutaneous bleeding: epistaxis, menorrhagia, easy bruising, and prolonged bleeding after procedures.</p>
                <p class="speakable">Labs show prolonged PTT, prolonged bleeding time, low VWF antigen and activity, and possibly low factor VIII.</p>
                <p class="speakable">Treatment for Type 1 is DDAVP which releases stored VWF. For Type 2 and 3 or major bleeding, give VWF concentrate.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">DIC</div>
            <div class="content-block high-yield"><div class="block-label">Key Points</div>
                <p class="speakable">DIC shows elevated PT and PTT, low fibrinogen, elevated D-dimer, low platelets, and schistocytes on smear.</p>
                <p class="speakable">Common triggers are sepsis, trauma, malignancy, obstetric complications, and transfusion reactions.</p>
                <p class="speakable">Treatment is supportive and treating the underlying cause. Transfuse blood products for active bleeding.</p>
            </div>
        </div>
    </div>
</div>
<div class="section" data-section="2">
    <div class="section-header"><span>3. Thrombocytopenia</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Approach</div>
            <div class="content-block"><div class="block-label">Differential</div>
                <p class="speakable">First rule out pseudothrombocytopenia from platelet clumping. Check smear and redraw in citrate tube.</p>
                <p class="speakable">Decreased production causes include bone marrow failure, infiltration, medications, infections, and nutritional deficiencies.</p>
                <p class="speakable">Increased destruction causes include ITP, TTP, HUS, DIC, HIT, and drug-induced.</p>
                <p class="speakable">Sequestration occurs with hypersplenism from portal hypertension or infiltrative diseases.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">TTP and HIT</div>
            <div class="content-block high-yield"><div class="block-label">TTP</div>
                <p class="speakable">TTP presents with thrombocytopenia, microangiopathic hemolytic anemia with schistocytes, fever, neurologic changes, and renal dysfunction.</p>
                <p class="speakable">Caused by ADAMTS13 deficiency leading to uncleaved VWF multimers.</p>
                <p class="speakable">ADAMTS13 activity less than 10 percent confirms diagnosis. Do not wait for results to treat.</p>
                <p class="speakable">Treatment is emergent plasma exchange plus steroids plus rituximab. Caplacizumab is an adjunct.</p>
                <p class="speakable">Do not transfuse platelets in TTP as it can worsen thrombosis.</p>
            </div>
            <div class="content-block high-yield"><div class="block-label">HIT</div>
                <p class="speakable">HIT typically occurs 5 to 10 days after starting heparin. Platelet drop greater than 50 percent or to less than 150,000.</p>
                <p class="speakable">Paradoxically causes thrombosis, not bleeding. Both arterial and venous clots can occur.</p>
                <p class="speakable">Calculate 4T score for pretest probability. If intermediate or high, send HIT antibody and start non-heparin anticoagulant.</p>
                <p class="speakable">Stop all heparin including flushes. Start argatroban, bivalirudin, or fondaparinux. Do not give warfarin until platelets recover.</p>
            </div>
        </div>
    </div>
</div>
<div class="section" data-section="3">
    <div class="section-header"><span>4. VTE & Anticoagulation</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Anticoagulation Duration</div>
            <div class="content-block"><div class="block-label">Guidelines</div>
                <p class="speakable">Provoked VTE from surgery or transient risk factor: 3 months of anticoagulation.</p>
                <p class="speakable">Unprovoked VTE: 3 months minimum, then reassess. Extended therapy if bleeding risk is low.</p>
                <p class="speakable">Recurrent unprovoked VTE or active cancer: indefinite anticoagulation.</p>
                <p class="speakable">Cancer-associated VTE: LMWH or DOAC preferred over warfarin. Continue while cancer is active or being treated.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Anticoagulant Reversal</div>
            <div class="content-block high-yield"><div class="block-label">Reversal Agents</div>
                <p class="speakable">Warfarin: Vitamin K for non-urgent reversal. 4-factor PCC plus vitamin K for urgent reversal.</p>
                <p class="speakable">Heparin and LMWH: Protamine sulfate. Reverses UFH completely, LMWH partially.</p>
                <p class="speakable">Dabigatran: Idarucizumab, brand name Praxbind.</p>
                <p class="speakable">Factor Xa inhibitors apixaban, rivaroxaban, edoxaban: Andexanet alfa. Use 4-factor PCC if unavailable.</p>
            </div>
        </div>
    </div>
</div>
<div class="section" data-section="4">
    <div class="section-header"><span>5. Hematologic Malignancies</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Leukemias</div>
            <div class="content-block high-yield"><div class="block-label">AML vs ALL</div>
                <p class="speakable">AML is more common in adults. Auer rods are pathognomonic. APL subtype shows t(15;17) and is treated with ATRA plus arsenic.</p>
                <p class="speakable">ALL is more common in children. Philadelphia chromosome t(9;22) is a poor prognostic marker.</p>
                <p class="speakable">CLL is the most common leukemia in Western adults. Smudge cells on smear. Many patients need no immediate treatment.</p>
                <p class="speakable">CML shows Philadelphia chromosome. Treat with tyrosine kinase inhibitors like imatinib.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Lymphomas</div>
            <div class="content-block"><div class="block-label">Hodgkin vs Non-Hodgkin</div>
                <p class="speakable">Hodgkin lymphoma has Reed-Sternberg cells. Bimodal age distribution. Often presents with mediastinal mass and B symptoms.</p>
                <p class="speakable">Non-Hodgkin lymphomas are a heterogeneous group. Most common is diffuse large B-cell lymphoma, which is aggressive. Follicular lymphoma is indolent.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Multiple Myeloma</div>
            <div class="content-block high-yield"><div class="block-label">CRAB Criteria</div>
                <p class="speakable">Myeloma causes hypercalcemia, renal insufficiency, anemia, and bone lesions, remembered as CRAB.</p>
                <p class="speakable">Diagnosis requires clonal bone marrow plasma cells 10 percent or more plus CRAB features or biomarkers of malignancy.</p>
                <p class="speakable">Biomarkers include 60 percent or more plasma cells, free light chain ratio 100 or more, or more than one MRI lesion.</p>
                <p class="speakable">SPEP shows M-spike. Serum free light chains are more sensitive than urine protein electrophoresis.</p>
            </div>
        </div>
    </div>
</div>
<div class="section" data-section="5">
    <div class="section-header"><span>6. Transfusion Medicine</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Transfusion Reactions</div>
            <div class="content-block high-yield"><div class="block-label">Types</div>
                <p class="speakable">Acute hemolytic reaction is due to ABO incompatibility. Presents with fever, flank pain, hemoglobinuria, and hypotension. Stop transfusion immediately.</p>
                <p class="speakable">Febrile non-hemolytic reaction is due to cytokines. Fever without hemolysis. Treat with acetaminophen. Use leukoreduced products.</p>
                <p class="speakable">Allergic reactions range from urticaria to anaphylaxis. Stop transfusion for severe reactions. Use washed products for recurrence.</p>
                <p class="speakable">TRALI presents with acute respiratory distress within 6 hours of transfusion. Bilateral infiltrates without volume overload. Supportive care.</p>
                <p class="speakable">TACO is volume overload presenting as pulmonary edema. Treat with diuretics.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Transfusion Thresholds</div>
            <div class="content-block"><div class="block-label">Guidelines</div>
                <p class="speakable">Restrictive strategy with hemoglobin threshold of 7 is appropriate for most stable hospitalized patients.</p>
                <p class="speakable">Threshold of 8 is used for cardiac surgery and symptomatic cardiovascular disease.</p>
                <p class="speakable">Platelet transfusion threshold is 10,000 for prophylaxis in stable patients. Higher thresholds for bleeding or procedures.</p>
            </div>
        </div>
    </div>
</div>
</div>
<div class="audio-controls">
    <div class="controls-row"><button class="control-btn" onclick="skipBackward()">‚è™</button><button class="control-btn play-btn" id="playPauseBtn" onclick="togglePlayPause()">‚ñ∂Ô∏è</button><button class="control-btn" onclick="skipForward()">‚è©</button><button class="control-btn" onclick="stopReading()">‚èπÔ∏è</button></div>
    <div class="progress-section"><span id="currentTime">0:00</span><div class="progress-bar" onclick="seekTo(event)"><div class="progress-fill" id="progressFill"></div></div><span id="totalTime">0:00</span></div>
    <div class="current-topic" id="currentTopic">Ready to play</div>
    <div class="settings-row"><div class="speed-control"><label>Speed:</label><select id="speedSelect" onchange="updateSpeed()"><option value="0.75">0.75√ó</option><option value="1" selected>1√ó</option><option value="1.5">1.5√ó</option><option value="2">2√ó</option></select></div><div class="pause-control"><label>Pauses:</label><select id="pauseSelect" onchange="updatePauses()"><option value="short">Short</option><option value="medium" selected>Medium</option><option value="long">Long</option></select></div></div>
</div>
<script>
let isPlaying=false,currentSentenceIndex=0,sentences=[],speechRate=1,englishVoices=[],pauseSettings={sentence:400,paragraph:800,section:1500};
document.addEventListener('DOMContentLoaded',()=>{loadVoices();buildSentenceList();setupTOC();const s=localStorage.getItem('heme_audio_pos');if(s)currentSentenceIndex=parseInt(s)||0;});
function loadVoices(){const sel=document.getElementById('voiceSelect');function pop(){const all=speechSynthesis.getVoices();englishVoices=all.filter(v=>v.lang.startsWith('en-'));if(!englishVoices.length){setTimeout(pop,100);return;}sel.innerHTML='';englishVoices.forEach((v,i)=>{const o=document.createElement('option');o.value=i;o.textContent=`${v.localService?'‚≠ê ':''}${v.name}`;sel.appendChild(o);});}pop();speechSynthesis.onvoiceschanged=pop;}
function buildSentenceList(){sentences=[];document.querySelectorAll('.speakable').forEach((el,i,arr)=>{const sec=el.closest('.section'),top=el.closest('.topic');sentences.push({text:el.textContent.trim(),element:el,section:sec?parseInt(sec.dataset.section):0,topic:top?.querySelector('.topic-title')?.textContent||'',isNewBlock:i===0||el.closest('.content-block')!==arr[i-1]?.closest('.content-block'),isNewSection:i===0||(sec?.dataset.section!==arr[i-1]?.closest('.section')?.dataset.section)});});updateProgress();}
function setupTOC(){document.querySelectorAll('.toc-item').forEach(item=>{item.addEventListener('click',()=>jumpToSection(parseInt(item.dataset.section)));});}
function jumpToSection(idx){const i=sentences.findIndex(s=>s.section===idx);if(i!==-1){currentSentenceIndex=i;if(isPlaying){speechSynthesis.cancel();speakCurrentSentence();}updateProgress();}}
function togglePlayPause(){isPlaying?pauseReading():startReading();}
function startReading(){isPlaying=true;document.getElementById('playPauseBtn').textContent='‚è∏Ô∏è';speakCurrentSentence();}
function pauseReading(){isPlaying=false;speechSynthesis.cancel();document.getElementById('playPauseBtn').textContent='‚ñ∂Ô∏è';localStorage.setItem('heme_audio_pos',currentSentenceIndex);}
function stopReading(){isPlaying=false;speechSynthesis.cancel();currentSentenceIndex=0;document.getElementById('playPauseBtn').textContent='‚ñ∂Ô∏è';updateProgress();localStorage.removeItem('heme_audio_pos');}
function speakCurrentSentence(){if(!isPlaying||currentSentenceIndex>=sentences.length){if(currentSentenceIndex>=sentences.length)stopReading();return;}const s=sentences[currentSentenceIndex],u=new SpeechSynthesisUtterance(s.text),vi=parseInt(document.getElementById('voiceSelect').value)||0;if(englishVoices[vi])u.voice=englishVoices[vi];u.lang='en-US';u.rate=speechRate;document.querySelectorAll('.current').forEach(el=>el.classList.remove('current'));s.element.classList.add('current');s.element.scrollIntoView({behavior:'smooth',block:'center'});document.getElementById('currentTopic').textContent=s.topic;updateProgress();u.onend=()=>{currentSentenceIndex++;if(currentSentenceIndex<sentences.length){let p=pauseSettings.sentence;if(sentences[currentSentenceIndex].isNewSection)p=pauseSettings.section;else if(sentences[currentSentenceIndex].isNewBlock)p=pauseSettings.paragraph;setTimeout(()=>{if(isPlaying)speakCurrentSentence();},p);}else stopReading();};speechSynthesis.speak(u);}
function updateProgress(){const pct=sentences.length?(currentSentenceIndex/sentences.length)*100:0;document.getElementById('progressFill').style.width=pct+'%';const avg=3/speechRate;document.getElementById('currentTime').textContent=Math.floor(currentSentenceIndex*avg/60)+':'+(Math.floor(currentSentenceIndex*avg)%60).toString().padStart(2,'0');document.getElementById('totalTime').textContent=Math.floor(sentences.length*avg/60)+':'+(Math.floor(sentences.length*avg)%60).toString().padStart(2,'0');}
function seekTo(e){currentSentenceIndex=Math.floor((e.offsetX/e.currentTarget.offsetWidth)*sentences.length);if(isPlaying){speechSynthesis.cancel();speakCurrentSentence();}updateProgress();}
function skipForward(){currentSentenceIndex=Math.min(currentSentenceIndex+10,sentences.length-1);if(isPlaying){speechSynthesis.cancel();speakCurrentSentence();}updateProgress();}
function skipBackward(){currentSentenceIndex=Math.max(currentSentenceIndex-10,0);if(isPlaying){speechSynthesis.cancel();speakCurrentSentence();}updateProgress();}
function updateSpeed(){speechRate=parseFloat(document.getElementById('speedSelect').value);updateProgress();}
function updatePauses(){const s=document.getElementById('pauseSelect').value;pauseSettings=s==='short'?{sentence:200,paragraph:400,section:800}:s==='long'?{sentence:600,paragraph:1200,section:2000}:{sentence:400,paragraph:800,section:1500};}
</script>
</body>
</html>
